阿托瓦斯塔丁的精确管理:遗传多态度的横截面分析
Razan Ibrahim1, Mohanad Odeh2, Eyad Mallah1
1Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
概括
这项研究开发了一种可靠的LC-MS/MS方法来测量血中的阿托瓦斯塔丁. 基因变异如CYP2D6-4显著影响阿托瓦斯塔丁水平,支持个性化超脂血症治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床化学 临床化学
- 遗传学 是一个遗传学.
背景情况:
- 超脂血是心血管疾病的关键危险因素.
- 遗传变异 (例如,CYP2D6-4) 影响阿托瓦斯塔丁的代谢和有效性.
- 个性化药物监测对于管理高脂血症至关重要.
研究的目的:
- 开发和验证一种LC-MS/MS方法来量化人类血中的阿托瓦斯塔丁.
- 研究基因多态性,特别是CYP2D6-4对阿托瓦斯塔丁血度的影响.
- 增强个性化的治疗药物监测和脂质配置管理.
主要方法:
- 使用液体染色学-并联质谱法 (LC-MS/MS) 量化阿托瓦斯塔丁.
- 使用基于聚合酶链反应 (PCR) 的方法进行基因型鉴定.
- 统计分析以将血阿托瓦斯塔丁水平与遗传变异相关联.
主要成果:
- 该LC-MS/MS方法显示了高准确性,精度,线性和稳定性.
- 较高的阿托瓦斯塔丁血度与CYP2D6-4遗传变异有关.
- 该分析方法已被验证为可靠的临床样本测量.
结论:
- 成功开发和验证了一种可靠的LC-MS/MS方法,用于在血中定量阿托瓦斯塔丁.
- CYP2D6-4和阿托瓦斯塔丁水平之间的强烈联系强调了药物遗传学剂量的重要性.
- 整合药物遗传学,特别是在约旦人群中,可以改善阿托瓦斯塔丁治疗的安全性,疗效和个性化.
相关概念视频
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
194
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
194
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:24Dosage Regimen: Individualization
165
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
165
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
269
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
269
01:05Single Nucleotide Polymorphisms-SNPs
17.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.9K
01:29Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196